Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

Exane BNP Paribas analyst Richard Parkes upgraded Novo Nordisk (NVO) to Outperform from Neutral with a DKK 930 price target The firm believes ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

We recently compiled a list of the Louis Navellier’s Top 10 Stock Picks Heading into 2025. In this article, we are going to ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...

Investing.com -- Healthcare stocks in the U.S. and Europe have tumbled since Donald Trump’s election victory on November 5, with concerns rising over the potential policy impact of his cabinet picks, ...

This follows the immense popularity of injectible GLP1R drugs, such as Novo Nordisk (Wegovy and Saxenda), Eli Lilly (Zepbound), and Shanghai Benemae Pharmaceutical (Yishengtai), approved for obesity.

The country sees securing equal access to innovative medicines as its presidency goal in pharma legislative talks.